Product Description
Longevity Biotech is currently developing LBT-3627 as a novel neuroprotective agent as a possible treatment for disorders such as Parkinson's Disease. LBT-3627 is a Hybridtide® that targets the VIP family of receptors - specifically the VPAC2 receptor subtype. Empirically, VPAC2 provides more protection than the closely related VPAC1 receptor. Together with the team at the University of Nebraska Medical Center, we have worked to determine the details regarding the protective mechanism along with functional endpoints. The results were recently published and describe a variety of experiments each providing insight into the unique immunomodulatory mechanism of action of LBT-3627. Longevity Biotech is actively progressing this program through preclinical development and towards clinical trials. Our initial focus is on neurodegenerative disorders, including Parkinson's Disease. (Sourced from: https://www.longevitybiotech.com/2016/neuroscience-lbt-3627/)
Mechanisms of Action: VPAC2 Inhibitor
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Longevity Biotech Australia Pty Ltd (subsidiary)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LBT-3627-101 | P1 |
Recruiting |
Parkinson's Disease |
2025-03-01 |